Can circulating tumor DNA guide treatment de-escalation in metastatic lung adenocarcinoma harboring actionable genomic alterations?

Transl Lung Cancer Res. 2024 Dec 31;13(12):3831-3834. doi: 10.21037/tlcr-24-861. Epub 2024 Dec 24.
No abstract available

Keywords: Epidermal growth factor receptor (EGFR); circulating tumor DNA (ctDNA); de-escalation; liquid biopsy (LB); non-small cell lung cancer (NSCLC).

Publication types

  • Editorial
  • Comment